Blood cancers

Novel TKI effective in CML patients intolerant to previous therapies

A novel tyrosine kinase inhibitor (TKI), asciminib, is showing promising clinical activity in patients with CML who have primary intolerance to prior TKI therapy, Australian research shows. Professor Timothy Hughes, Precision Medicine Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI) presented new results at EHA25 Virtual from a phase 1 study ...

Already a member?

Login to keep reading.

© 2020 the limbic